clinical trial · NCT04456998
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.·phase2·completed·n = 86
Pulmonary Artery HypertensionGB002 (seralutinib)PlaceboGeneric Dry Powder Inhaler
brief summary
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.
started
Nov 12, 2020
primary completion
Oct 17, 2022
completion
Nov 1, 2022
last updated
Nov 7, 2023
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol